Our Compound

CNS Disease Cases are Increasing

Fullerene Therapeutics is concerned with degenerative diseases of the central nervous system such as:

  • Parkinson’s
  • Alzheimer’s
  • Amyotrophic lateral sclerosis (ALS)
  • Multiple sclerosis
  • Huntington’s chorea
Many of these are primarily found in older adults as they are thought to be at least partly the result of cellular deterioration. As the world’s population ages, the number of people with diseases of the central nervous system is also increasing.

The World Health Organization now estimates the number of CNS disease sufferers to potentially be as high as 140 million worldwide and this population is expected to grow at a compound rate exceeding 10 percent annually for the foreseeable future.

The five major CNS diseases exact three distinct tolls on society:

  • Treatment costs are large and rising — $250 billion in the U.S. alone in 2006.
  • Productivity losses are high — an estimated $500 billion a year in the U.S. from work that cannot be performed by CNS patients.
  • The cost of morale and spirit to both patients and their families.

Copyright 2019 Fullerene Therapeutics, Inc.
No part of the contents of this web site may be 
reproduced without express written permission.